Delving into the Latest Updates on Shenge Bushen Capsules with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Taizi Shenyue Capsule, Taizi Shenyue Jiaonang, 太子神悦胶囊

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Depressive Disorder

Inactive Indication-

Originator Organization

Xinjiang Huachun Biopharmaceutical Co., Ltd.

Active Organization

Xinjiang Huachun Biopharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (29 Dec 2022),

Depressive Disorder

Regulation-

Login to view timeline

Taking the reduction of Hamilton Depression Rating Scale as the main efficacy indicator, compared with the positive drug fluoxetine hydrochloride capsules and placebo, the effectiveness and safety of Taizi Shenyue Capsule in the treatment of mild and moderate depression (insufficiency of Qi and Yin, deficiency of both heart and spleen) were confirmed, providing a review basis for the new drug registration application of Taizi Shenyue Capsule.

Start Date10 Dec 2012

Sponsor / Collaborator

BEIJING YINGHUA CO., LTD.

100 Clinical Results associated with Shenge Bushen Capsules

Login to view more data

100 Translational Medicine associated with Shenge Bushen Capsules

Login to view more data

100 Patents (Medical) associated with Shenge Bushen Capsules

Login to view more data

100 Deals associated with Shenge Bushen Capsules

Login to view more data